Axon Enterprise Interest Expense 2011-2025 | AXON

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Axon Enterprise

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
286 M	-41.9 M	99 M	25.3 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
286 M	-41.9 M	92.2 M

Quarterly Interest Expense Axon Enterprise

2025-Q1	2024-Q4	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
114 M	-	139 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
139 M	114 M	127 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
AbbVie ABBV	2.81 B	$ 223.01	-0.99 %	$ 395 B	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.68	1.85 %	$ 777 M	Canada
Aclaris Therapeutics ACRS	2.95 M	$ 3.38	3.21 %	$ 261 M	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Ascendis Pharma A/S ASND	65.5 M	$ 212.3	5.5 %	$ 5 B	Danmark
BioVie BIVI	4.3 M	$ 1.54	-2.53 %	$ 2.28 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.4	1.49 %	$ 8.18 B	Australia
Amphastar Pharmaceuticals AMPH	4.08 M	$ 25.76	0.19 %	$ 1.25 B	USA
Aytu BioScience AYTU	-512 K	$ 2.33	2.3 %	$ 14.6 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Biogen BIIB	250 M	$ 173.03	-2.55 %	$ 25.2 B	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 0.29	-5.01 %	$ 631 M	Israel
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
Benitec Biopharma BNTC	-126 K	$ 12.91	0.78 %	$ 531 M	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-7.26 M	$ 11.55	8.86 %	$ 747 M	USA
Enochian Biosciences ENOB	122 K	-	-	$ 40.5 M	USA
Catalyst Biosciences CBIO	1.04 M	$ 15.32	5.73 %	$ 1.01 B	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Cerus Corporation CERS	1.98 M	$ 2.14	13.23 %	$ 395 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Bristol-Myers Squibb Company BMY	-893 M	$ 51.05	-0.32 %	$ 103 B	USA
Abeona Therapeutics ABEO	418 K	$ 5.5	0.46 %	$ 118 M	USA
ADiTx Therapeutics ADTX	5.84 K	$ 2.36	-7.29 %	$ 31.1 K	USA
BioXcel Therapeutics BTAI	20.2 M	$ 2.1	-4.34 %	$ 5.32 M	USA
Coherus BioSciences CHRS	40.5 M	$ 1.42	6.77 %	$ 134 M	USA
BioLineRx Ltd. BLRX	9.07 M	$ 3.22	-2.72 %	$ 908 M	Israel
Celldex Therapeutics CLDX	927 K	$ 28.33	0.5 %	$ 1.82 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Baudax Bio BXRX	1.36 M	-	0.59 %	$ 63 K	USA